| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
DYRK1A 220 nM (IC50) DYRK1A 3 nM (Kd) DYRK1B 56 nM (Kd)
DYRK1-IN-1 targets DYRK1A. It is a highly selective and ligand-efficient DYRK1A inhibitor. It inhibits DYRK1A phosphorylation activity with an IC50 value of 220 nM. By inhibiting DYRK1A, it can modulate tau phosphorylation. DYRK1A is a kinase involved in various cellular processes, including neuronal development and tau phosphorylation. |
|---|---|
| ln Vitro |
DYRK1-IN-1 has an IC50 value of 220 nM, which inhibits DYRK1A's phosphorylation activity. With an IC50 value of 0.59 μM, DYRK1-IN-1 suppresses the phosphorylation of tau. Without P-glycoprotein liability, DYRK1-IN-1 has good permeability and cellular activity. strong physicochemical characteristics, high levels of enzymatic efficacy, strong aqueous solubility, outstanding kinome selectivity, and a promising inhibitory target in vitro are all displayed by DYRK1-IN-1. A 434 nM IC50 and an enzymatic IC50 of 75 nM demonstrate satisfactory cellular activity in DYRK1-IN-1 (HEK293 cells)[1].
DYRK1-IN-1 demonstrates in vitro activity as a DYRK1A inhibitor with an IC50 of 220 nM. It inhibits tau phosphorylation with an IC50 of 0.59 μM. The compound shows good permeability and cellular activity. In cell-based assays, DYRK1-IN-1 inhibits DYRK1A-mediated phosphorylation events, including tau phosphorylation. Its ability to modulate tau phosphorylation is a key measure of its cellular activity. |
| ln Vivo |
The clearance of DYRK1-IN-1 (1 mg/kg; intravenous) is high[1].
DYRK1-IN-1 is used as a chemical probe to study the biological functions of DYRK1A and its potential as a therapeutic target for neurological and cognitive disorders. It is expected to have CNS penetration. In vivo studies are needed to fully characterize its efficacy and safety profile in animal models of neurological disorders. |
| Enzyme Assay |
The in vitro enzyme/receptor binding (non-cell-based) assay for DYRK1-IN-1 involves assessing its inhibition of DYRK1A kinase activity. Recombinant DYRK1A is incubated with the compound, ATP, and a substrate peptide. Kinase activity is measured by detecting the phosphorylation of the substrate. The IC50 value of 220 nM is determined from dose-response curves.
|
| Cell Assay |
The in vitro cell-based assay for DYRK1-IN-1 involves treating cells with the compound and measuring its effects on DYRK1A-mediated phosphorylation events, such as tau phosphorylation. Cells are treated with the compound, and tau phosphorylation is assessed by Western blotting. The IC50 of 0.59 μM for tau phosphorylation is determined.
|
| Animal Protocol |
Animal/Disease Models: Sprague−Dawley rats[1]
Doses: 1 mg/kg (pharmacokinetic/PK Analysis) Route of Administration: Iv Experimental Results: High clearance was observed. In vivo animal experiments for DYRK1-IN-1 are conducted in models of neurological disorders. The compound is administered to animals, and its effects on DYRK1A activity, tau phosphorylation, and cognitive function are assessed. Its CNS penetration is evaluated. The compound's ability to modulate tau pathology and improve cognitive function is assessed in these models. |
| ADME/Pharmacokinetics |
DYRK1-IN-1 has a molecular weight of 2814486-79-6. It is soluble in DMSO at 20 mg/mL. The compound is typically stored as a powder at -20°C. It is typically used for research purposes only.
|
| Toxicity/Toxicokinetics |
As a research compound, its safety profile is evaluated in standard cytotoxicity and acute toxicity assays. The compound is classified for research use only and is not intended for human therapeutic use. Comprehensive toxicological characterization would be required prior to any clinical development. The compound is typically handled with standard laboratory safety precautions.
|
| References | |
| Additional Infomation |
DYRK1-IN-1 (CAS 2814486-79-6) is a highly selective DYRK1A inhibitor. It has an IC50 of 220 nM for DYRK1A and inhibits tau phosphorylation with an IC50 of 0.59 μM. It is used as a chemical probe for neurological research. It is not approved for clinical use and is available only for research purposes.
|
| Molecular Formula |
C12H12N6
|
|---|---|
| Molecular Weight |
240.263880729675
|
| Exact Mass |
240.112
|
| CAS # |
2814486-79-6
|
| PubChem CID |
138454302
|
| Appearance |
White to off-white solid powder
|
| LogP |
1
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
18
|
| Complexity |
284
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN(C)C1=NC=CC(=N1)C2=C3C=CC=NN3N=C2
|
| InChi Key |
IFLBFWBMAWIBBZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H12N6/c1-17(2)12-13-7-5-10(16-12)9-8-15-18-11(9)4-3-6-14-18/h3-8H,1-2H3
|
| Chemical Name |
N,N-dimethyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 25 mg/mL (104.05 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.41 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1622 mL | 20.8108 mL | 41.6216 mL | |
| 5 mM | 0.8324 mL | 4.1622 mL | 8.3243 mL | |
| 10 mM | 0.4162 mL | 2.0811 mL | 4.1622 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
